Managing mechanical valves with reduced anticoagulation
| Autor: | Mark S. Slaughter, Eias Jweied |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Treatment outcome Heart Valve Diseases Prosthesis Design Prosthesis Risk Assessment Mechanical valve Drug Administration Schedule Thromboembolism Replacement heart valve Internal Medicine Prosthesis design Medicine Humans Thrombotic risk Bioprosthesis Heart Valve Prosthesis Implantation Dose-Response Relationship Drug business.industry Warfarin Anticoagulants General Medicine Survival Analysis Frequent use Surgery Treatment Outcome Heart Valve Prosthesis Female Cardiology and Cardiovascular Medicine business medicine.drug Follow-Up Studies |
| Zdroj: | Expert review of cardiovascular therapy. 5(6) |
| ISSN: | 1744-8344 |
| Popis: | The choice of replacement heart valve has alternated many times during the past 40 years. The reason for the change is related to the balance between prosthesis longevity and the need for anticoagulation therapy. Bioprosthetic valves do not require continuous anticoagulation therapy but their expected life can be less than the patient's. Anticoagulation therapy for mechanical valves carries the risk of bleeding or thromboembolism. Research shows progress toward a mechanical valve that has a reduced thrombotic risk which may reduce the anticoagulation therapy requirements. Patient self-management of anticoagulation therapy results in more effective therapy with lower doses of anticoagulants. The current trend is more frequent use of bioprosthetic valves; however, this trend may again reverse as therapy for mechanical valves is refined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|